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OBJECTIVES The purpose of this study was to investigate the association among insulin resistance, high
density lipoprotein cholesterol (HDL-C) and coronary heart disease (CHD), and to test the
hypothesis that HDL-C may ameliorate the adverse effects of insulin.
BACKGROUND Serum low HDL-C (hypoalphalipoproteinemia) and hyperinsulinemia are independent
predictors for CHD, but a strong negative correlation exists between them, as in patients with
syndrome X.
METHODS Fifty-four pairs of cases (M/F: 49/5), defined as patients with angiographically proved CHD,
and control subjects (M/F: 49/5) matched with cases with regard to gender and age were
included. Insulin resistance was assessed by the homeostasis model assessment (HOMA).
RESULTS Cases had increased HOMA insulin resistance and lower serum levels of HDL-C than
controls. A receiver operating characteristic (ROC) curve analysis indicated that HDL-C and
insulin resistance were significant discriminators of CHD (area under ROC curve: 0.72 and
0.69, respectively). The interaction between HDL-C and the association of insulin resistance
with CHD was significant: subjects with hyperinsulinemia and high HDL-C had no
increased risk of CHD. Multivariate conditional logistic regression analysis showed that
hyperinsulinemic hypoalphalipoproteinemia was a stronger indicator for CHD than either
HDL-C or insulin resistance alone (22 log likelihood: 19.0 vs. 12.6 or 15.7).
CONCLUSIONS Hyperinsulinemic hypoalphalipoproteinemia was a more potent indicator for CHD than
either insulin resistance or low serum HDL-C levels alone, and the adverse effects of
hyperinsulinemia seem to be ameliorated by high HDL-C levels. (J Am Coll Cardiol 1999;
34:1443–51) © 1999 by the American College of Cardiology
An inverse relationship between plasma levels of high
density lipoprotein cholesterol (HDL-C) and coronary
heart disease (CHD) has been well established (1–3). Direct
evidence for the antiatherogenic effects of HDL has recently
been obtained in studies of the over- or underexpression
of apolipoprotein (apo) A-I using genetic animal models
of reverse cholesterol transport (4 – 8). Several large
population-based prospective studies have identified hyper-
insulinemia as an independent risk factor of CHD (9–13).
Hyperinsulinemia, as a compensatory response to insulin
resistance, has been strongly associated with decreased
HDL-C and other metabolic abnormalities that are second-
ary to hyperinsulinemia, as in the multiple metabolic syn-
drome and insulin resistance syndrome (“syndrome X”)
(14).
Because hyperinsulinemia and low HDL (hypoalpha-
lipoproteinemia) strongly correlate but predict the risk of
CHD independently, it is of great interest whether or not
these two variables interact in their association with CHD.
However, this point has not been investigated previously.
Therefore, in the present case-control study, we assessed the
influence of serum levels of HDL-C on the association
between insulin resistance as determined by the homeostasis
model assessment (HOMA) model (15) and CHD.
METHODS
Patients. Cases (patients with CHD) were selected from
patients who underwent diagnostic coronary angiography
for suspected or known coronary atherosclerosis or for other
reasons (mostly atypical chest pain) at Fukuoka University
Hospital from 1994 to 1997 and were defined as those who
had one, two or three stenosed (.50% luminal narrowing)
epicardial coronary arteries (n 5 85, F/M: 12/73, age:
62.1 6 10.6 years). Control subjects (those subjects without
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CHD, n 5 111, F/M: 52/59, age: 57.5 6 12 years) were
selected from those who had come to our heart clinic for a
medical check up or because they had various symptoms
(without episodes of chest pain) and were confirmed to be
free of CHD based on their medical history, exercise-stress
electrocardiogram or negative results of single photon emis-
sion computed tomography (SPECT). This study was
approved by the ethics committee of Fukuoka University
Hospital and informed consent was obtained from each
patient. Patients with diabetes mellitus (DM), acute myo-
cardial infarction (MI) (within three weeks after onset),
heart failure (Killip class $2 after MI), vascular disease
(aortitis treated by prednisolone) or hepatic dysfunction
(virus and nonvirus, transaminases more than three times
the normal value) were excluded from the study. Patients
with systolic or diastolic blood pressure .140 mm Hg or
90 mm Hg or who were receiving antihypertensive treat-
ment were considered to have hypertension (HT). Patients
who were being treated for DM or who had symptoms of
DM and a fasting glucose concentration $126 mg/dl were
considered to have DM. Otherwise, the results of a 75-g
oral glucose tolerance test were used to diagnose DM. None
was receiving hormone replacement therapy.
Of the 85 patients with CHD and 111 control subjects,
54 pairs of cases and controls were selected by matching
them on a one-to-one basis with regard to gender and age.
The categoric variable, gender, was matched perfectly. Age
was matched by applying the minimum-distance case-
control matching method (16,17). The largest difference
between a case and a control was three years (control
subjects were 61 year of the case’s age). Thirty-one cases
and 53 control subjects were rejected because they did not
match.
Coronary angiography. Coronary arteries were cannulated
by the Judkins technique (18) with 5F catheters and
recorded on Kodak 35 mm cinefilm at a rate of 25 frames/s.
Coronary arteries were divided into 15 segments according
to the classification of the American Heart Association
Grading Committee. Coronary artery segments were care-
fully selected by two expert cardiologists on the basis of
smooth luminal borders and the absence of stenotic
changes. The presence of stenoses was determined using a
computer-assisted coronary angiography analysis system
(Micron 1; Kontron Co., Tokyo, Japan) after the direct
intracoronary injection of isosorbide dinitrate (ISDN) (2.5
mg/5 ml solution), as described previously (19–21). Arterial
stenosis that produced more than 50% luminal narrowing
was considered significant.
Determination of lipids, lipoproteins and apolipopro-
teins. Blood was drawn in the morning after an overnight
fast. Serum total cholesterol (TC), triglyceride (TG),
HDL-C, apo A-I, apo A-II and apo B were determined as
described previously (21).
Estimation of insulin resistance. Plasma glucose concen-
trations were measured by the glucose oxidase method, and
plasma immunoreactive insulin concentrations were mea-
sured by a standard radioactive immunoassay. Insulin resis-
tance was estimated with the HOMA model (15), using
fasting plasma insulin and glucose concentrations. The
HOMA insulin resistance has been shown to correlate well
with insulin resistance measured using a euglycemic clamp
(r 5 0.88, p , 0.0001) (15).
Statistical analysis. Statistical analysis was performed us-
ing the SAS Software Package (Version 6.12, Statistical
Analysis System, SAS Institute Inc., Cary, North Carolina)
at Fukuoka University. Categoric variables (such as gender)
and frequency distribution patterns of insulin resistance and
serum HDL-C in cases and controls were compared by a
chi-square analysis (22). The distribution of continuous
variables was examined by the Shapiro-Wilk test (22).
Differences in continuous variables between pairs of cases
and control subjects were examined by a repeated measures
analysis of variance (ANOVA) (23), and other variables,
such as body mass index (BMI), were adjusted for by a
repeated measures analysis of covariance (ANCOVA) (23).
Correlations between HOMA insulin resistance and lipid
variables were examined by the Pearson correlation (23).
Linear relationships between continuous variables were
examined by linear regression models with least-squares
fitting (24). Interaction effects between regression lines were
examined by the general linear model (24).
The predictive value of HOMA insulin resistance and
HDL-C as continuous variables was assessed using a re-
ceiver operating characteristic (ROC) curve analysis (25,26).
Sensitivity was calculated as true positives/(true positives 1
false negatives) and specificity was calculated as true nega-
tives/(true negatives 1 false positives) (27). A ROC curve
Abbreviations and Acronyms
ANCOVA 5 analysis of covariance
ANOVA 5 analysis of variance
apo 5 apolipoprotein
BMI 5 body mass index
CHD 5 coronary heart disease
CI 5 confidence interval
DM 5 diabetes mellitus
HDL-C 5 high density lipoprotein cholesterol
HOMA 5 homeostasis model assessment
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ISDN 5 isosorbide dinitrate
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(plot of sensitivity vs. 12specificity) analysis is a powerful
tool for assessing a test’s ability to discriminate between two
groups of subjects and does not depend on the threshold
(cutoff) value selected. The area under the ROC curve
represents the probability for a randomly chosen disease-
free subject (control) to exhibit a value lower (such as
HOMA insulin resistance) or higher (such as HDL-C)
than the level observed among randomly chosen diseased
subjects (cases). A value of 0.5 means that the distributions
of the values in the two groups are similar; conversely, a
value of 1 means that distributions of values in the two
groups do not overlap. We determined the area under the
ROC curve by the trapezoidal rule, as in a linear logistic
regression model (28), and evaluated its significance by the
Wald chi-square test (28). The ROC curve also allows
variable thresholds to be determined based on a target
sensitivity or specificity. We set the cutoff value for each
continuous variable at 0.70 (70%) specificity by using a
modified ROC analysis in which we constructed and ap-
plied a “two-graph-ROC” plot (29,30). Dummy variables
were produced using these cutoff values. A dummy variable
was given a value of 0 for subjects with a value less than (,)
or equal to (5) the cutoff value (low-value group) and a
value of 1 for those with a value higher than (.) the cutoff
value (high-value group).
The interaction effects of HDL-C with the association
between HOMA insulin resistance and CHD were exam-
ined both: 1) by plotting the differences in HOMA insulin
resistance between cases and controls versus HDL-C levels
(continuous) of cases and testing the significance of the
linear trend, and 2) by stratifying all of the subjects
according to their HDL-C levels (two levels) and then
testing significance of the difference in HOMA insulin
resistance between cases and controls for the low-HDL-C
and high HDL-C strata (groups) by the Wilcoxon rank-
sum test (24).
The associations of HOMA insulin resistance and
HDL-C with the risk of CHD in 54 pairs of cases and
gender- and age-matched control subjects were examined by
a conditional logistic regression analysis with the propor-
tional hazards regression (PHREG) procedure (28), by
using the discrete logistic model and forming a stratum for
each matched set. For each continuous variable, the cutoff
value upon which to base dummy variables was chosen to
give a specificity of 70%. We examined the interdependence
of the associations of HOMA insulin resistance and
HDL-C with CHD and adjusted for other lipid variables
and conventional risk factors by a multivariate conditional
logistic regression analysis (28). Independent indicators for
the presence of CHD were also selected by a stepwise
conditional logistic regression analysis (28). For all of the
adjusted odds ratios, we calculated 95% confidence intervals
(CIs). For regression coefficients in the conditional logistic
regression analysis, we showed the standard error. All p
values are two-tailed. The significance level was considered
to be 5% unless otherwise indicated.
RESULTS
Table 1 shows the characteristics of 54 pairs of cases and
control subjects matched with regard to gender and age. No
statistically significant differences in age, BMI, HT or
smoking status were found between cases and control
subjects.
Figure 1 shows the frequency distributions of insulin
resistance as assessed by the HOMA model (15), as well as
serum levels of HDL-C in cases and control subjects. As
shown in Figure 1A, distribution of the HOMA insulin
resistance was significantly different between cases and
controls; the distribution of HOMA insulin resistance in
cases was shifted toward higher values compared with that
in control subjects. By definition, one third of control
subjects were found in each tertile of HOMA insulin
resistance. In contrast, a smaller proportion of cases (14.8%)
was found within the first tertile, and a larger proportion of
cases (64.8%) was found within the third tertile. As shown
in Figure 1B, the distribution of serum HDL-C levels was
also significantly different between cases and controls; the
distribution of HDL-C in cases shifted toward lower values
compared with that in control subjects. A larger proportion
of cases (68.5%) compared with controls (35.2%) was found
within the first tertile of HDL-C, and a smaller proportion
of cases (5.6%) was found within the third tertile.
Table 2 compares fasting levels of plasma glucose and
insulin, HOMA insulin resistance, and serum levels of
lipids, HDL-C and apolipoproteins in 54 pairs of cases and
controls matched by gender and age. Cases had significantly
higher values of fasting insulin (10.0 6 6.3 mU/ml vs. 6.1 6
3.4 mU/ml, p , 0.05) and HOMA insulin resistance (2.3 6
1.5 vs. 1.4 6 0.8, p , 0.05) and lower levels of serum
HDL-C (42.0 6 10.8 mg/dl vs. 52.9 6 17.1 mg/dl, p ,
0.05), apo A-l and apo A-II than control subjects, as
assessed by a repeated measures ANOVA (23). No signif-
icant differences in fasting levels of plasma glucose or serum
levels of TC and TG were observed between cases and
controls. Therefore, cases, as compared with controls, were
characterized by hyperinsulinemia that compensated for
insulin resistance.
Because cases and control subjects were matched for age
by the minimum-distance matching method (17), we tested
the interaction effects of age with the effects of HOMA
Table 1. Clinical Characteristics of the 54 Pairs of Cases (with
CHD) and Control Subjects
Controls
(n 5 54)
Cases
(n 5 54)
Age (yr) 60.8 6 9.3 61.0 6 9.3
Gender 49/5 49/5
Body mass index, kg/m2 23.8 6 2.7 24.2 6 3.5
Hypertension, % 33 (61.1%) 26 (48.2%)
Smokers, % 20 (37.0%) 26 (51.8%)
Values are mean 6 SD.
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insulin resistance and HDL-C on the risk of CHD by
plotting the differences in these two variables between cases
and control subjects versus the age of the cases, respectively
(data not shown), and assessing the significance of the linear
trend by a regression analysis. In both cases, the null
hypothesis of no linear trend could not be rejected with p
values of 0.91 and 0.17, respectively, which shows that the
matching variable, age, had no interaction effects with the
relation between HOMA insulin resistance, HDL-C and
CHD.
Figure 2A shows the ROC curves (25,26) of HOMA
Figure 1. Frequency distributions of (A) insulin resistance as
assessed by the HOMA model and (B) serum levels of HDL-C in
54 pairs of cases with coronary heart disease (solid bars) and
controls (open bars). The frequency distributions of HOMA
insulin resistance and HDL-C were each significantly different
between the two groups (chi-square 5 19.2 and 23.8, df 5 7, p ,
0.01). The proportion of cases in each tertile of HOMA insulin
resistance (Fig. 1A) and HDL-C (Fig. 1B) is also shown, along
with their corresponding mean values 6 SD. Arrows on the X axis
identify the tertile values (solid arrows on the left and right, 0.96
and 1.43 for HOMA insulin resistance and 45 and 56 mg/dl for
HDL-C) and the median value (open arrows in the middle, 1.21
for HOMA insulin resistance and 53 mg/dl for HDL-C) of
control subjects.
Figure 2. (A) ROC curves of the true-positive rate (sensitivity)
versus the false-positive rate (12specificity) for HOMA insulin
resistance. The smooth curves are model-fitted curves by the
method of Swets (26). (B) Two-graph ROC plots of the sensitivity
(solid lines) and specificity (dotted lines) curves from the ROC
curve analysis versus HOMA insulin resistance. Cutoff values were
defined to give 70% specificity.
Table 2. Plasma Glucose and Insulin Levels and Serum Levels
of Lipids, HDL-C, and Apolipoproteins in 54 Pairs of Cases
and Controls
Controls
(n 5 54)
Cases
(n 5 54)
Fasting glucose, mg/dl 94 6 9 95 6 11
Fasting insulin, mU/ml 6.1 6 3.4 10.0 6 6.3*
HOMA insulin
resistance
1.4 6 0.8 2.3 6 1.5*
HDL-C, mg/dl 52.9 6 17.1 42.0 6 10.8*
Apo A-I, mg/dl 132 6 32 107 6 21*
Apo A-II, mg/dl 31.9 6 7.3 28.0 6 4.5*
Apo B, mg/dl 116 6 29 107 6 23
Total cholesterol, mg/dl 206 6 34 197 6 39
Triglyceride, mg/dl 141 6 69 166 6 100
*p , 0.05, cases vs. control subjects, assessed by a repeated measures analysis of
variance (23). Data are presented as mean values 6 standard deviation.
apo 5 apolipoprotein; HDL-C 5 high density lipoprotein cholesterol; HOMA
insulin resistance, relative insulin resistance estimated by the HOMA model (15).
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insulin resistance. As shown, HOMA insulin resistance
showed a moderate ability to discriminate cases from con-
trols. Table 3 (left and middle columns) shows the areas
under the ROC curves for continuous variables. As shown,
fasting plasma insulin levels (area under ROC curve, 0.701,
p , 0.01), HOMA insulin resistance (0.694, p , 0.01) and
serum levels of HDL-C (0.716, p , 0.01), apo A-I and apo
A-II showed significant discriminative ability for CHD.
The predicative value of insulin resistance and HDL-C for
CHD were similar as indicated by their area under the
ROC curve. Figure 2B shows the two-graph-ROC plots
(29) for HOMA insulin resistance, to demonstrate how the
cutoff value for making dummy variables was determined.
As shown, cutoff values were those that gave a specificity of
0.7 (70%). Table 3 (right column) shows the cutoff values of
continuous variables (1.48 for HOMA insulin resistance
and 43.6 mg/dl for HDL-C).
In all of the subjects, HOMA insulin resistance showed
strong correlations with BMI (r 5 0.27, p , 0.01), fasting
plasma levels of glucose and insulin (r 5 0.28 and 0.98, p ,
0.01) and serum levels of HDL-C and apo A-I (r 5 20.36
and 20.30, p , 0.01). Correlation coefficients were essen-
tially similar in cases and control subjects, except for
HDL-C. As shown in Figure 3A, the regression lines of
HOMA insulin resistance versus HDL-C in the cases
(regression coefficient 6 SE 5 20.046 6 0.018, t 5 22.46,
p , 0.05) and control subjects (regression coefficient 6
SE 5 20.014 6 0.007, t 5 22.05, p , 0.05) interacted at
a significance level of less than 0.1 (F value 5 3.23, p 5
0.075), as assessed by an ANCOVA (23); for example,
HOMA insulin resistance in cases increased more than that
in controls with decreasing HDL-C levels (Fig. 3A).
Because a significant inverse correlation was found be-
tween HOMA insulin resistance and HDL-C (Fig. 3A),
the interaction of HDL-C with the association between
HOMA insulin resistance and CHD was tested in two
ways: by treating HDL-C as a continuous (Fig. 3B) or a
category variable (Fig. 4), respectively. As illustrated in
Figure 3B, the differences in HOMA insulin resistance
between cases and control subjects were greater for cases
with lower HDL-C than for those with higher HDL-C. In
fact, the average difference approached zero at an HDL-C
level of 50 mg/dl. This interaction was significant as tested
by assessing the linear trend (regression coefficient 6 SE 5
20.056 6 0.026, t 5 22.15, p , 0.05). As shown in Figure
4, when HDL-C was used as a stratification variable (two
levels), HOMA insulin resistance appeared to be more
strongly related to CHD for the low HDL-C stratum than
for the high HDL-C stratum. These results suggest that
HDL-C may ameliorate the adverse effects of HOMA
insulin resistance.
To examine the contribution of HOMA insulin resis-
tance to the risk of CHD and its interdependence with
HDL-C, a series of multivariate conditional logistic analy-
ses to predict the case-control status were performed (Table
4). As illustrated in model 1, the risk of CHD for subjects
Figure 3. (A) Correlation between serum levels of HDL-C and
HOMA insulin resistance in 54 pairs of cases (solid circles) and
control subjects (open circles). Regression lines for cases and
controls are shown by solid and dotted lines, respectively. (B)
Differences in HOMA insulin resistance between cases and
gender- and age-matched controls plotted against HDL-C in the
case patient and fitted by linear regression.
Table 3. Area Under Receiver Operating Characteristic Curves
and Cutoff Values for Continuous Variables
Variables
Area
Under
ROC
Curve
p
Value*
Cutoff Value
at Specificity
of 0.7
Body mass index 0.536 n.s. 24.6
Fasting glucose, mg/dl 0.511 n.s. 89.0
Fasting insulin, mU/ml 0.701 , 0.01 5.95
HOMA insulin
resistance
0.694 , 0.01 1.48
HDL-C, mg/dl 0.716 , 0.01 43.6
Apo A-I, mg/dl 0.752 , 0.01 108
Apo A-II, mg/dl 0.689 , 0.05 25.6
Apo B, mg/dl 0.615 n.s. 107
Total cholesterol, mg/dl 0.568 n.s. 204
Triglyceride, mg/dl 0.564 n.s. 146
*Significance of the area under the ROC curve as examined by the Wald chi-square
test.
HDL-C 5 high density lipoprotein cholesterol; HOMA insulin resistance 5
relative insulin resistance as assessed by the homeostasis model assessment (HOMA)
(15).
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with high HOMA insulin resistance was 3.7-fold (95% CI,
1.6 to 8.4) higher (p , 0.01) than that in subjects with low
HOMA insulin resistance. As shown in model 2, the risk of
CHD for high HDL-C was 3.1 (1/0.32)-fold (95% CI, 1.4
[1/0.69] to 6.7 [1/0.15]) lower (p , 0.01) than that for low
HDL-C. As shown in model 3, inclusion of both HOMA
insulin resistance and HDL-C in the same model attenu-
ated to some extent the associations between HOMA
insulin resistance and CHD (odds ratio [95% CI]: 3.0 [1.2
to 7.0], p , 0.05) and between low HDL-C and CHD (2.4
[1/0.42], 1.1 [1/0.95] to 5.3 [1/0.19], p , 0.05), but these
associations remained significant (Table 4). Further adjust-
ment for TC (model 4), TG (model 5) and BMI, HT and
smoking status together (model 6) had very little influence
on the relationships between HOMA insulin resistance,
HDL-C and CHD (Table 4). These results suggest that
high HOMA insulin resistance (hyperinsulinemia) and low
HDL are independent indicators for CHD.
Because the association between HOMA insulin resis-
tance and CHD varied with the HDL-C level, as shown in
Figure 4, we combined HOMA insulin resistance and low
HDL-C into one variable (hyperinsulinemic hypoalphali-
poproteinemia), which was given a value of 1 if both high
HOMA insulin resistance and low HDL-C were present
and a value of 0 for all other cases (high-HOMA insulin
resistance and high-HDL-C or low-HOMA insulin resis-
tance and high HDL-C or low-HOMA insulin resistance
and low HDL-C) and compared the predictive value of
hyperinsulinemic hypoalphalipoproteinemia with those of
hyperinsulinemia and hypoalphalipoproteinemia, after ad-
justing for conventional risk factors (Table 5). As shown in
Table 5, the presence of hyperinsulinemic hypoalpha-
lipoproteinemia was more strongly associated with the risk
of CHD than either hyperinsulinemia or hypoalphalipopro-
teinemia alone, as judged by the model fitting criterion, 22
log likelihood (28). The interdependence of these variables
based on their association with CHD was examined by a
stepwise conditional logistic regression analysis (Table 6).
As shown in the upper panel of Table 6, both hyperinsu-
linemia and hypoalphalipoproteinemia were selected as
independent indicators for CHD when hyperinsulinemia,
hypoalphalipoproteinemia, TC, TG, BMI, HT and smok-
ing status were included in the model as independent
variables (model 1). As shown in the lower panel of Table 6,
only hyperinsulinemic hypoalphalipoproteinemia was se-
lected as an independent indicator for CHD, when hyper-
insulinemic hypoalphalipoproteinemia was added to model
1 as an independent variable (model 2), which agrees with
the results in Table 5. These results suggest that the
combination of HOMA insulin resistance and low HDL-C
was a better indicator for CHD than either insulin resis-
tance or HDL-C alone.
Figure 4. Odds ratios for CHD (95% confidence interval in
parenthesis) and probability levels (top of bar) according to insulin
resistance as assessed by the HOMA model (15) and high density
lipoprotein cholesterol (HDL-C). Cutoff values at a specificity of
0.7 (70%) were used to make dummy variables. Odds ratios were
obtained by a conditional logistic regression analysis and are
adjusted for covariates (body mass index, hypertension and smok-
ing status). CHD 5 coronary heart disease.
Table 4. Associations Among HOMA Insulin Resistance, HDL-C and CHD Before and After Adjusting for Concomitant Variation
in Serum Lipids and Conventional Risk Factors: Multivariate Conditional Logistic Analysis of 54 Case-Control Pairs
Independent
Variables
Odds Ratio (95% Confidence Intervals)
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
HOMA insulin resistance 3.7*
(1.6–8.4)
3.0†
(1.2–7.0)
3.0†
(1.3–7.1)
3.0†
(1.3–7.3)
3.4†
(1.4–8.7)
HDL-C 0.32*
(0.15–0.69)
0.42†
(0.19–0.95)
0.40†
(0.17–0.92)
0.39†
(0.17–0.92)
0.36†
(0.14–0.93)
Total cholesterol 1.3
(0.55–3.0)
1.3
(0.55–3.0)
1.4
(0.57–3.3)
Triglyceride 0.92
(0.40–2.1)
0.84
(0.35–2.0)
BMI, HT, smoking status 2.2
(0.81–5.8)
*p , 0.01; †p , 0.05, significant association between the independent variable and risk of CHD. For HOMA insulin resistance, BMI and lipid variables, dummy variables defined
by a cutoff value of 70% specificity were used.
BMI 5 body mass index; HT 5 hypertension.
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Figure 4 also shows the odds ratios for the combination of
HOMA insulin resistance and HDL-C. As shown, the
respective risk of CHD in subjects with high HOMA
insulin resistance and high HDL-C (odds ratio [95% CI]:
2.2 [0.65 to 7.5], ns.) and in those with low HOMA insulin
resistance and low HDL-C (1.6 [0.41 to 6.3], ns.) were not
significantly increased relative to low-HOMA insulin resis-
tance high-HDL-C subjects (1.0). However, subjects with
high HOMA insulin resistance and low HDL-C had an
8.7-fold higher (2.5 to 30, p , 0.001) risk of CHD than
subjects with low-HOMA insulin resistance and high-
HDL-C, which is much higher than could be expected by
a multiplicative model (3.5 5 2.2 3 1.6) (31), suggesting
that hyperinsulinemia and hypoalphalipoproteinemia syner-
gistically increase the risk of CHD.
In summary, HOMA insulin resistance and HDL-C are
independently associated with CHD. However, the adverse
effects of hyperinsulinemia may be ameliorated by high
HDL-C levels. Hyperinsulinemic hypoalphalipoprotein-
emia was a more potent indicator for CHD than either
increased insulin resistance or low HDL-C alone. Increased
HOMA insulin resistance and low HDL-C increase the
risk of CHD synergistically.
DISCUSSION
Hyperinsulinemia and insulin resistance are main character-
istics of syndrome X and result in secondary syndrome X
features, including hyperglycemia, increased very low den-
sity lipoprotein (VLDL) concentrations, decreased HDL-C
and HT (14). The antiatherogenic effects of HDL have
been directly documented by studies using transgenic ani-
mal models (4–8). Therefore, we tested the hypothesis that
HDL-C levels may ameliorate the adverse effects of insulin
resistance.
ROC analysis of the ability of insulin resistance and
HDL-C to predict CHD. In the present case-control
study, cases were patients with angiographically proved
CHD, and non-CHD controls were matched with cases for
gender (perfect matching) and age (minimum-distance
matching), because gender and age are strongly correlated
with both the prevalence of CHD and the predicative
variables, i.e., HOMA insulin resistance and HDL-C.
Table 5. Comparison of the Association Among Hyperinsulinemia, Hypoalphalipoproteinemia
and CHD With the Association Between Hyperinsulinemic Hypoalphalipoproteinemia and
CHD by a Conditional Logistic Regression Analysis of 54 Case-Control Pairs
Variable
Regression
Coefficient
(Standard Error)* Wald x2 p Value
22 Log
Likelihood
High insulin resistance 1.35 6 0.45 9.04 0.0026 15.7
Low HDL-C 1.16 6 0.45 6.55 0.011 12.6
High insulin resistance
and low HDL-C
1.80 6 0.54 11.21 0.0008 19.0
*All models include the following covariables: body mass index (1 5 high, 0 5 low), hypertension (1 5 yes, 0 5 no) and smoking
status (1 5 yes, 0 5 no).
Table 6. Stepwise Conditional Logistic Regression Analysis of Variables Associated with CHD
and Conventional Risk Factors
Variable Entered Into the Model
Regression
Coefficient 6
Standard Error* Wald x2 p Value
Model 1*
Hyperinsulinemia 1.09 6 0.44 6.18 0.01
Hypoalphalipoproteinemia 0.86 6 0.41 4.38 0.04
Model 2†
Hyperinsulinemic
hypoalphalipoproteinemia
1.67 6 0.48 12.17 0.0005
*Independent variables were insulin resistance (1 5 high, 0 5 low), HDL-C (1 5 low, 0 5 high), total cholesterol (1 5 high,
0 5 low), triglyceride (1 5 high, 0 5 low), body mass index (1 5 high, 0 5 low), hypertension (1 5 yes, 0 5 no) and smoking
status (1 5 yes, 0 5 no).
†Independent variables were hyperinsulinemic hypoalphalipoproteinemia (1 5 presence, 0 5 absence), HOMA insulin
resistance, HDL-C, total cholesterol, triglyceride, body mass index, hypertension and smoking status.
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Cases, compared with control subjects, were character-
ized by hyperinsulinemia, as indicated by higher fasting
levels of insulin, and normal glucose levels (Table 2). This is
consistent with the findings of several large population
studies that have investigated the association between hy-
perinsulinemia and CHD (10–13). Our finding that cases
had lower serum levels of HDL-C, apo A-I and apo A-II
(Table 2) agrees with the established inverse relationship
between HDL and CHD (1–3).
The results of our ROC curve analysis (25,26), which did
not depend on the cutoff value, showed that HDL-C and
insulin resistance are significant discriminators for CHD
and have a similar discriminatory ability. Although the
associations between hyperinsulinemia and CHD and be-
tween HDL-C and CHD have been extensively studied, the
discriminatory abilities of these two predictors have not
been previously compared.
Relationship between insulin resistance and HDL-C.
Our finding that insulin resistance (hyperinsulinemia) was
inversely correlated with HDL-C is consistent with the
results of other studies (32–34). Although the mechanism of
this association is not quite clear, enhanced hepatic lipase
activity and the impaired activity of the insulin-dependent
enzyme lipoprotein lipase observed in type II DM have been
suggested to play a role (35). We also observed a strong
positive correlation between insulin resistance (hyperinsu-
linemia) and serum TG levels in controls (data not shown).
A direct relationship between insulin and hypertriglyceride-
mia has also been suggested by other studies (32–34).
Increased fatty acid production and impaired VLDL clear-
ance in type II DM have been proposed as possible
underlying mechanisms (35).
Conditional logistic regression analysis of the association
among insulin resistance, HDL-C and CHD. Because a
logistic regression analysis using dummy variables does not
depend on the distribution of predicative variables, a con-
ditional logistic regression analysis was used to examine the
association among the prevalence of CHD, HDL-C and
insulin resistance in pairs of cases and gender- and age-
matched control subjects. Our finding that HDL-C and
insulin resistance are independent indicators of CHD after
considering confounding variables (Table 4) is consistent
with many previous studies (1–3,9–13).
Influence of HDL-C on the association between insulin
resistance and CHD. Our findings that insulin resistance
was inversely correlated with HDL-C levels in both cases
and control subjects, yet with different regression coeffi-
cients (Fig. 3A), and was associated with CHD indepen-
dent of HDL-C, encouraged us to test the interaction of
HDL-C with the association between insulin resistance and
CHD. Our hypothesis that the adverse effects of hyperin-
sulinemia on CHD may be ameliorated by high HDL-C
levels was supported by our finding of a significant interac-
tion effect (Fig. 3B and 4; the association between insulin
resistance and CHD was significant when HDL-C was low
but not significant when HDL-C was high), and by our
finding that hyperinsulinemic hypoalphalipoproteinemia
was a stronger indicator for CHD than either insulin
resistance or low HDL-C alone, as assessed by a multivar-
iate conditional logistic regression analysis (Tables 5 and 6).
In addition, our results also suggest that hyperinsulinemia
and hypoalphalipoproteinemia increase the risk of CHD
synergistically (Fig. 4). The interaction between insulin
resistance and HDL-C in their association with CHD has
not been investigated previously.
There is some evidence that insulin may promote athero-
genesis by directly affecting the arterial wall. In animal
studies, insulin enhances the development of atherosclerotic
plaque (36), and in vitro, insulin has been shown to cause
smooth muscle cell proliferation (37), stimulate low density
lipoprotein binding to smooth muscle cells (38), fibroblasts
(39) and monocytes (40); it also stimulates cholesterol
synthesis in monocytes (41). It has been shown that high
levels of HDL protect against CHD, possibly due to its role
in reverse cholesterol transport (42). Recent studies in
transgenic mice have indicated that HDLs are directly
antiatherogenic (4). New evidence suggests that HDLs
inhibit the expression of cell adhesion molecules that are
required for the interaction between leukocytes and the
endothelium in the early stage of the development of early
atherosclerosis (43). Therefore, the adverse effects of hyper-
insulinemia on CHD may be ameliorated by HDLs.
Study limitations. We examined the association among
insulin resistance, HDL-C and CHD in a case-control
study. However, whether or not HDL-C has a causal effect
on the association of hyperinsulinemia with CHD cannot
be determined from a case-control study.
Conclusions. Insulin resistance (hyperinsulinemia) as as-
sessed by the HOMA model and serum levels of HDL-C
are independently associated with CHD. However, the
adverse effects of hyperinsulinemia seem to be ameliorated
by high HDL-C levels. This report is the first to note that
insulin resistance and low HDL-C levels may synergistically
increase the risk of CHD and that hyperinsulinemic hy-
poalphalipoproteinemia was a more potent indicator for
CHD than either insulin resistance or serum HDL-C levels
alone.
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